You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

GSK2248761

Showing 1 - 12 of 12
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Infection, Human Immunodeficiency Virus, HIV Trial in Buffalo (GSK2248761 formulation 1, GSK2248761 reference formulation,

Completed
  • Infection, Human Immunodeficiency Virus
  • HIV Infections
  • GSK2248761 formulation 1
  • +3 more
  • Buffalo, New York
    GSK Investigational Site
Mar 25, 2020

Drug Exposure Registry for GSK2248761, an Investigational NNRTI

Completed
Has Results
  • HIV Infections
    • (no location specified)
    Jul 31, 2019

    Infection, Human Immunodeficiency Virus, HIV Trial in Fargo (YASMIN, GSK2248761, Placebo)

    Terminated
    • Infection, Human Immunodeficiency Virus
    • HIV Infections
    • Fargo, North Dakota
      GSK Investigational Site
    Feb 18, 2019

    Infection, Human Immunodeficiency Virus Trial in Buenos Aires (GSK2248761, Lopinavir/ritonavir, HAART)

    Completed
    Has Results
    • Infection, Human Immunodeficiency Virus
    • GSK2248761
    • +3 more
    • Buenos Aires, Argentina
      GSK Investigational Site
    May 4, 2018

    Infection, Human Immunodeficiency Virus Trial in France, Germany, Spain (GSK2248761 100 mg once daily, GSK2248761 200 mg once

    Terminated
    Has Results
    • Infection, Human Immunodeficiency Virus
    • GSK2248761 100 mg once daily
    • +2 more
    • Levallois Perret, France
    • +11 more
    Oct 16, 2017

    Infection, Human Immunodeficiency Virus Trial in Buffalo (Raltegravir, GSK2248761, GSK2248761 + Raltegravir)

    Completed
    • Infection, Human Immunodeficiency Virus
    • Buffalo, New York
      GSK Investigational Site
    Sep 8, 2017

    Infection, Human Immunodeficiency Virus Trial in Worldwide (GSK2248761 100 mg once daily, GSK2248761 200 mg once daily,

    Terminated
    Has Results
    • Infection, Human Immunodeficiency Virus
    • GSK2248761 100 mg once daily
    • +2 more
    • Birmingham, Alabama
    • +40 more
    Oct 12, 2017

    Infections, Human Immunodeficiency Virus and Herpesviridae, Infection, Human Immunodeficiency Virus Trial in Buffalo (GSK2248761

    Completed
    • Infections, Human Immunodeficiency Virus and Herpesviridae
    • Infection, Human Immunodeficiency Virus
    • GSK2248761 WBM Capsule
    • +4 more
    • Buffalo, New York
      GSK Investigational Site
    Jun 6, 2017

    Infection, Human Immunodeficiency Virus I Trial in Buffalo (GSK1349572, GSK2248761)

    Withdrawn
    • Infection, Human Immunodeficiency Virus I
    • Buffalo, New York
      GSK Investigational Site
    Dec 22, 2014

    Infection, Human Immunodeficiency Virus Trial in Madison (200mg [14C]- GSK2248761)

    Withdrawn
    • Infection, Human Immunodeficiency Virus
    • 200mg [14C]- GSK2248761
    • Madison, Wisconsin
      GSK Investigational Site
    May 15, 2014

    Infection, Human Immunodeficiency Virus Trial in Austin (GSK2248761, Simvastatin, Atorvastatin)

    Completed
    • Infection, Human Immunodeficiency Virus
    • GSK2248761
    • +3 more
    • Austin, Texas
      GSK Investigational Site
    Nov 4, 2010

    Healthy Subjects, Infection, Human Immunodeficiency Virus Trial in Baltimore (darunavir/ritonavir, lopinavir/ritonavir,

    Completed
    • Healthy Subjects
    • Infection, Human Immunodeficiency Virus
    • Baltimore, Maryland
      GSK Investigational Site
    Nov 2, 2010